Posts tagged as: new technologies in diabetes management back to homepage

ALR Technologies Stock Chart Analysis Video ALR Technologies Stock Chart Analysis Video(0)

A look at the three-year weekly chart for ALR Technologies (OTCBB: ALRT) shows a baseline pattern and support at 6 cents with additional support at 7 cents. Higher lows have been progressively made over the three years with a top-end resistance at 24 cents. The chart is just above Read More

Taglich Brothers Issues “Speculative Buy” and $0.50 Target on ALR Technologies Taglich Brothers Issues “Speculative Buy” and $0.50 Target on ALR Technologies(0)

Research firm Taglich Brothers has initiated coverage on ALR Technologies, Inc. (OTCBB: ALRT); issuing a “Speculative Buy” rating and a $0.50 12-month price target on the healthcare technology company and developer of the Health-e-Connect (HeC) system.  HeC is an FDA-cleared Internet-based system from chronic disease management.  A scalable technology for a wide array of chronic diseases, HeC is initially being marketed by ALR Technologies as a solution Read More

ALR Technologies Files 10-K with SEC ALR Technologies Files 10-K with SEC(0)

ALR Technologies, Inc. (OTCBB: ALRT) products utilize internet based technologies to facilitate health care providers the ability to monitor their patient’s health and ensure adherence to health maintenance activities.

The Company’s Health-e-Connect (HeC) system is an internet based product initially intended for patients with diabetes and their health care providers to improve communication and monitoring of patients’ health Read More

ALR Technologies Investor Call Video ALR Technologies Investor Call Video(0)

Yesterday, ALR Technologies, Inc. (OTCBB:ALRT) hosted an investor call to discuss recent corporate developments and their proprietary Health-e-Connect (HeC) system with investors. The HeC system received 510(k) marketing clearance from the Food and Drug Administration in the fourth quarter of 2011. The company has been working towards market launch of the HeC system and, according to CEO Sidney Chan, expects to be generating sales of the system in 2012. Read More

ALR Technologies to Host Investor Meeting Discussing Diabetes Management Technology ALR Technologies to Host Investor Meeting Discussing Diabetes Management Technology(0)

ALR Technologies, Inc. (OTCBB:ALRT) is hosting an investor meeting/webinar after the markets close on Monday, March 19, 2012 at 4:30 PM EDT.  CEO and Chairman Sidney S. Chan will be providing an investor presentation to discuss corporate developments and product launch as well as conducting a question and answer session about the company and its Health-e-Connect (HeC) system for chronic disease management.  ALR Technologies received FDA 510(k) marketing clearance for their HeC system as a new solution for diabetes management in the fourth quarter of 2011. Read More

ALR Technology Updates Shareholders on Diabetes Management System(0)

ALR Tech Meets With U.S. Business Leaders, Policymakers: Talks Focus on How Health-e-Connect Can Improve Patient Outcomes, Lower Healthcare Costs

ALR Technologies Inc. (OTCBB: ALRT) (the “Company”), a healthcare technology company, is pleased to provide shareholders with an update on corporate developments since receiving 510(k) clearance from the U.S. Food and Drug Administration for its Health-e-Connect (HeC) System for remote monitoring of patients in support of effective diabetes management Read More

ALR Technologies: Penny Stock, Recent FDA Clearance, Enormous Potential(0)

ALR Technologies Inc. (OTCBB: ALRT), an innovative medical device company, offers a unique software solution aimed at improving patient adherence to care plans  in the diabetes industry working alongside companies like Abbott Laboratories (NYSE: ABT) and Bayer AG (PINK: BAYRY) that develop diabetes testing supplies. Read More

PositiveID to Launch Clinical Trials for Breath Glucose Detection PositiveID to Launch Clinical Trials for Breath Glucose Detection(0)

Diabetes management technology developer PositiveID Corporation (OTCBB: PSID) is readying to launch its first clinical trial later in January 2012 for its Easy Check™ non-invasive breath glucose detection device for people with diabetes. The Florida-based company said that initial trials will focus on persons with Read More

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.